RFP QuestBeta
OpenStage · award

THE UNIVERSITY OF BIRMINGHAM

ACT2 Study

Value£515k
Deadline
Published14 Jul 2025
RegionNationwide
Who to contact
procurement@bham.ac.uk

The procurement contact named on the official notice.

Match for your company
Sign up free to see how well this tender matches your company — the score, the signals that align, and where the gaps are.
The brief

University of Birmingham (UoB) is the sponsor of ACT2 (Allogeneic Chondrocyte Therapy - A phase 2a study), an MRC funded project (MR/V027670/1).

The study commenced in 2021 with the aim to develop and manufacture an allogeneic chondroprogenitor cell therapy from fresh osteochondral allografts in order to treat cartilage lesions in a single surgery.

The study requires a manufacturing facility that can work with the research team to develop and validate the manufacturing process of the cell therapy product to a standard that can gain MHRA approval and thus enable the commencement of a Phase 2a human trial.

Due to unforeseen circumstances, previously contracted GMP manufacturers are no longer able to manufacture the cell therapy product and, thus an alternative manufacturing facility is required expeditiously.

The UoB team must operate within the restrictions placed upon them by the funder and the current project plan.

In addition to this, the administrative burden as a consequence of BREXIT makes the use of a UK laboratory the only viable option.

The Newcastle Advanced Therapies Facility has the unique requirements to deliver the project within the financial and time restrictions facing the project.

Key requirements

What the supplier must deliver

01

Due to unforeseen circumstances, previously contracted GMP

Due to unforeseen circumstances, previously contracted GMP manufacturers are no longer able to manufacture the cell therapy product and, thus an alternative manufacturing facility is required expeditiously.

02

The UoB team must operate within

The UoB team must operate within the restrictions placed upon them by the funder and the current project plan.

03

The Newcastle Advanced Therapies Facility has

The Newcastle Advanced Therapies Facility has the unique requirements to deliver the project within the financial and time restrictions facing the project.

Derived from the notice text — always confirm against the original documents.

Buyer intelligence

Make the case to bid

Reveal who to approach at THE UNIVERSITY OF BIRMINGHAM, and generate a go-to-market strategy from their news, accounts and people.

Source & provenance
OCID
ocds-h6vhtk-055e22
Stage
award · Awarded
Source
Find a Tender
Buyer ref
039471-2025
View the original notice on Find a Tender

Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.

Market context

Who wins this kind of work

The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.

THE UNIVERSITY OF BIRMINGHAM’s tender network

Assembling the network…